Presentation, Management, and Outcomes of Urinary Bladder Paraganglioma: Results From a Multicenter Study
- 26 July 2022
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (10) , 2811-2821
Abstract
Context: Urinary bladder paraganglioma (UBPGL) is rare. Objective: We aimed to characterize the presentation and outcomes of patients diagnosed with UBPGL. Methods: We conducted a multicenter study of consecutive patients with pathologically confirmed UBPGL evaluated between 1971 and 2021. Outcomes included repeat bladder surgery, metastases, and disease-specific mortality. Results: Patients (n=110 total; n=56 [51%] women) were diagnosed with UBPGL at a median age of 50 years (interquartile range [IQR], 36-61 years). Median tumor size was 2 cm (IQR, 1-4 cm). UBPGL was diagnosed prior to biopsy in only 37 (34%), and only 69 (63%) patients had evaluation for catecholamine excess. In addition to the initial bladder surgery, 26 (25%) required multiple therapies, including repeat surgery in 10 (9%). Synchronous metastases were present in 9 (8%) patients, and 24 (22%) other patients with UBPGL developed metachronous metastases at a median of 4 years (IQR, 2-10 years) after the initial diagnosis. Development of metachronous metastases was associated with younger age (hazard ratio [HR] 0.97; 95% CI, 0.94-0.99), UBPGL size (HR 1.69; 95% CI, 1.31-2.17), and a higher degree of catecholamine excess (HR 5.48; 95% CI, 1.40-21.39). Disease-specific mortality was higher in patients with synchronous metastases (HR 20.80; 95% CI, 1.30-332.91). Choice of initial surgery, genetic association, sex, or presence of muscular involvement on pathology were not associated with development of metastases or mortality. Conclusions: Only a minority of patients were diagnosed before biopsy/surgery, reflecting need for better diagnostic strategies. All patients with UBPGL should have lifelong monitoring for development of recurrence and metastases.Keywords
Funding Information
- National Institutes of Health (K23DK121888, #KL2 TR001879)
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
This publication has 17 references indexed in Scilit:
- Clinicopathologic Characteristics and Mutational Status of Succinate Dehydrogenase Genes in Paraganglioma of the Urinary Bladder: A Multi-Institutional Korean StudyArchives of Pathology & Laboratory Medicine, 2016
- Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patientsJournal of Medical Genetics, 2015
- Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genesUrologic Oncology: Seminars and Original Investigations, 2015
- Genetics and the Clinical Approach to ParagangliomasHormone and Metabolic Research, 2014
- Identification of Succinate Dehydrogenase–deficient Bladder ParagangliomasAmerican Journal of Surgical Pathology, 2013
- Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literatureBMC Urology, 2013
- Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or ParagangliomasThe Journal of Clinical Endocrinology & Metabolism, 2007
- Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardousSurgery, 2007
- Benign Paragangliomas: Clinical Presentation and Treatment Outcomes in 236 PatientsThe Journal of Clinical Endocrinology & Metabolism, 2001
- Fine-needle aspiration of catecholamine-producing adrenal masses: a possibly fatal mistakeAmerican Journal of Roentgenology, 1985